Free Trial

Fortrea (FTRE) Stock Forecast & Price Target

Fortrea logo
$19.15 +0.47 (+2.52%)
(As of 11/20/2024 ET)

Fortrea - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
8
Buy
3

Based on 12 Wall Street analysts who have issued ratings for Fortrea in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 1 has given a sell rating, 8 have given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for FTRE.

Consensus Price Target

$24.50
27.94% Upside
According to the 12 analysts' twelve-month price targets for Fortrea, the average price target is $24.50. The highest price target for FTRE is $30.00, while the lowest price target for FTRE is $20.00. The average price target represents a forecasted upside of 27.94% from the current price of $19.15.
Get the Latest News and Ratings for FTRE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Fortrea and its competitors.

Sign Up

FTRE Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
7 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$24.50$23.60$27.20$31.75
Forecasted Upside27.94% Upside32.58% Upside23.47% Upside-3.35% Downside
Consensus Rating
Hold
Hold
Hold
Hold

FTRE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FTRE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fortrea Stock vs. The Competition

TypeFortreaMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside27.94% Upside26,931.55% Upside9.81% Upside
News Sentiment Rating
Positive News

See Recent FTRE News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024TD Cowen
4 of 5 stars
 Boost TargetHold ➝ Hold$23.00 ➝ $25.00+3.01%
11/11/2024Barclays
3 of 5 stars
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$20.00 ➝ $25.00+8.74%
11/11/2024Robert W. Baird
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$28.00 ➝ $30.00+27.66%
11/8/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform
10/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetIn-Line ➝ In-Line$22.00 ➝ $20.00+7.70%
10/8/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$26.00 ➝ $23.00+24.06%
Download Our Tesla Ebook For Free (Ad)

Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.
9/25/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$25.00 ➝ $21.00-5.45%
8/20/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$28.00 ➝ $23.00+2.72%
8/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderperform ➝ Underperform$26.00 ➝ $21.00-3.93%
8/13/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$42.00 ➝ $30.00+44.44%
5/28/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$27.00+5.68%
5/14/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:37 AM ET.


FTRE Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Fortrea is $24.50, with a high forecast of $30.00 and a low forecast of $20.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortrea in the last twelve months. There is currently 1 sell rating, 8 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" FTRE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FTRE, but not buy additional shares or sell existing shares.

According to analysts, Fortrea's stock has a predicted upside of 27.94% based on their 12-month stock forecasts.

Over the previous 90 days, Fortrea's stock had 1 downgrade by analysts.

Fortrea has been rated by research analysts at Barclays, Evercore ISI, Jefferies Financial Group, Robert W. Baird, TD Cowen, The Goldman Sachs Group, and William Blair in the past 90 days.

Analysts like Fortrea less than other "medical" companies. The consensus rating for Fortrea is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FTRE compares to other companies.


This page (NASDAQ:FTRE) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners